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Abstract: Restless legs syndrome (RLS) is a condition characterized by discomfort at rest and 
urge to move focused on the legs. RLS may occur as an idiopathic, often hereditary condition 
(primary RLS), or in association with medical conditions (secondary RLS) including iron 
deficiency, uremia, and polyneuropathy. Current understanding of the pathophysiology of RLS 
points to the involvement of three interrelated components: dopaminergic dysfunction, impaired 
iron homeostasis, and genetic mechanisms. The diagnosis of RLS is made according to the 
consensus criteria by a National Institutes of Health panel: 1) an urge to move the legs, usually 
accompanied by uncomfortable sensations; 2) beginning or worsening during rest; 3) relieved by 
movement; and 4) worse, or only occurring, in the evening or at night. The differential diagnosis 
of RLS aims to: 1) distinguish RLS from other disorders with RLS-like symptoms and 2) identify 
secondary forms, with investigation of underlying diseases. The treatment of RLS demands a 
clinical evaluation to rule out and cure causes of secondary RLS, including iron supplementation 
when deficient, and to eliminate the triggering factors. The presence of neuropathy should be 
especially investigated in nonhereditary, late-onset RLS, in view of a possible treatment of the 
underlying disease. The first line treatment for idiopathic RLS is represented by dopamine agonists, 
in particular nonergot-derived ropinirole and pramipexole, whereas ergot dopamine agonists 
(cabergoline and pergolide) are no longer in first-line use given the risks of cardiac valvulopathy. 
Although no comparative trials have been published, a meta-analysis of pramipexole versus 
ropinirole suggests differences in efficacy and tolerability favoring pramipexole.
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Introduction
Restless legs syndrome (RLS) is a common, yet overlooked condition, mainly charac-
terized by discomfort at rest and urge to move focused on the legs, first described by 
Willlis1 in 1672, and recently re-defined by consensus criteria put forth by a National 
Institutes of Health (NIH) panel.2
Most of the epidemiological studies that have employed adequate diagnostic 
criteria3 report prevalences of RLS (men and women combined) between 6% and 
12%,4 when conducted in Western populations, but when distinguishing between 
the mere presence of RLS and clinically significant RLS (with symptoms frequent 
or severe enough to require treatment), the prevalence of this latter approaches 3%.5 
The prevalence of RLS is distinctly lower in Asian populations, ranging from 0.1% 
in Singapore6 to 4.6% in elderly Japanese.7
RLS may occur as an idiopathic, often hereditary condition (primary RLS), or in 
association with several medical conditions (secondary RLS) such as iron deficiency,8 Clinical Interventions in Aging 2009:4 306
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end-stage renal diseases,9 pregnancy,10 rheumatologic 
disorders,11,12 diabetes,13,14 as well as neurologic conditions 
such as Parkinson’s disease,15 spinal cord lesions,16 multiple 
sclerosis,18 and polyneuropathy.18
The association of RLS with polyneuropathy is of 
particular interest from epidemiological, mechanistic, and 
diagnostic viewpoints, but is still controversial, in spite of 
extensive studies. Prevalence estimates of RLS in neuropa-
thy are extremely variable, ranging from 5.2%19 to 54%.20 
In a series of 104 consecutive patients with miscellaneous 
neuropathies, we found a 29% prevalence of RLS, compared 
to 9% in controls.18 A prevalence of RLS of 54% was found 
in a selected series of patients with neuropathy with symp-
toms of pain or dysesthesia.20 On the contrary, in a recent 
controlled, double-blind study, the prevalence of RLS in 
neuropathy patients (12.2%) did not differ significantly 
from controls (8.2%), but in the subgroup of patients with 
hereditary neuropathy a higher prevalence of 19.4% was 
found.21 Conflicting results may be due to methodological 
discrepancies in the design of the studies and in the assess-
ment of RLS and of neuropathy, and variations in etiology 
of neuropathy between cohorts; in addition, it should be 
considered that, as polyneuropathy is usually an evolutive 
condition, the appearance or disappearance of RLS may be 
related to different phases of the disease. As it has been shown 
that RLS can be triggered by small fiber sensory neuropa-
thy,18,22–24 it is expected that RLS prevalence in neuropathy 
will be higher when considering the forms with prevailing 
small fiber involvement, such as diabetic neuropathy.14,25 In 
conclusion, we think that the prevalence of RLS in the course 
of polyneuropathy should be further assessed separately in 
different subtypes, segregated either by etiology or on the 
basis of preferentially involved nerve fiber population.
Current understanding of the pathophysiology of RLS 
points to the involvement of three interrelated components: 
dopaminergic dysfunction, impaired iron homeostasis, and 
genetic mechanisms.26 In particular, dopamine dysfunction 
plays a central role, as suggested by the early observation that 
dopaminergic drugs are highly effective in treating RLS.27 
Increasing data support the hypothesis that dysfunctioning 
dopaminergic pathway resides in the small diencephalospi-
nal tract originating from the hypothalamic A11 nucleus,16 
modulating the excitability of sensorimotor spinal circuits 
presumably subserving RLS.28,29 Dysfunction of endogenous 
opioidergic circuits, possibly mediated by an interaction 
with the dopaminergic system, has been also implicated, 
based on the positive clinical response to opioidergic 
agents.30 Recently, in a PET study with an aspecific opioid 
receptor ligand, von Spiczak and colleagues found a negative 
correlation between RLS severity and the ligand binding in 
thalamus, amygdale, and anterior cingulated gyrus, structures 
involved in the medial pain system.31
Alterations in iron metabolism probably intersect with 
dopamine signaling, for instance as a consequence of the 
role of iron as cofactor for tyrosine hydroxylase.8 Further, 
dopaminergic transmission may be affected by genetic 
factors, which however may also influence RLS at different 
neural levels, underlying changes of other motor and/or 
sensory structures possibly implicated in RLS.29 Finally, 
abnormal hyperexcitability of spinal circuits in RLS could 
be induced not only by impaired descending dopaminergic 
modulation, but also by changes in the spinal cord itself,28 or 
by abnormal peripheral inputs in peripheral nervous system 
(PNS) diseases.18
Diagnosis
The diagnosis of RLS is made according to the NIH criteria,2 
that is: 1) an urge to move the legs, usually accompanied or 
caused by uncomfortable or unpleasant sensations in the legs; 
2) beginning or worsening during periods of rest or inactivity 
such as lying or sitting; 3) partially or totally relieved by 
movement such as walking or stretching; 4) worse in the 
evening or at night than during the day, or only occurring in 
the evening or night. In addition, supportive clinical features 
are considered (Table 1), which include, besides positive 
family history and response to dopaminergic therapy, the 
occurrence of periodic limb movements (PLMs) during 
wakefulness or sleep. PLMs are stereotyped rhythmic 
movements characterized by extension of the big toe and 
dorsiflexion of the ankle, which are recorded in standard 
polysomnography by surface electromyogram of anterior 
tibialis.32 A pathological number of PLMs (5 PLMs/hour of 
sleep) is found in about 80% of RLS patients.33 and correlates 
with RLS severity.34,35 PLMs, however, are not specific for 
RLS, occurring in a variety of sleep disorders and also in 
normal people. PLMs can be a useful second level diagnostic 
tool in selected patients with uncertain RLS diagnosis who 
deserve instrumental investigations.
The diagnostic criteria have been summarized in a 
comprehensive definition of RLS as “movement-responsive 
quiescegenic nocturnal focal akathisia usually with 
dysesthesias”.36
There are two major steps in the differential diagnosis 
of RLS: 1) distinguishing RLS from other disorders with 
RLS-like symptoms; and 2) the individuation of secondary 
forms, with investigation of underlying diseases.Clinical Interventions in Aging 2009:4 307
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Conditions that resemble RLS (RLS “mimics”) include 
those with motor restlessness and those with a variety of 
leg pains or discomfort.36 Motor restlessness is character-
istic for neuroleptic-induced akathisia, which, however, 
is usually generalized, with more stereotyped body and 
limb movements, while in RLS there is an urge to move 
a particular part of the body; patients with neuroleptic-
induced akathisia do not experience sensory discomfort 
as an antecedent to motor restlessness, and often have no 
relief by movement. Nocturnal leg cramps are relieved 
with stretching or walking, but no urge to move is experi-
enced, and painful muscular contraction is clearly unlike 
RLS sensations. Positional discomfort comes on with 
prolonged sitting or lying in the same position, but it is usu-
ally relieved by a simple change in position, unlike RLS, 
without a true circadian pattern, if not because during the 
night the rest increases the chances to maintain the same 
position. Volitional movements such as foot tapping and 
leg rocking, occurring in conditions of uneasiness, usually 
are not associated with sensory symptoms, discomfort, 
or conscious urge to move. Painful legs and moving toes 
involve mainly feet and toes, with slow writhing move-
ments, in the absence of either conscious urge to move or 
circadian pattern. Various painful conditions, neurological 
or nonneurological, such as myelopathy, radiculopathy, 
peripheral neuropathy, lower limb arthritis, nighttime 
pain in the lower limbs in the course of congestive heart 
failure, may have symptoms that are worse at night, and 
cause sleep disturbances, but there is no urge to move and 
relief by movement.
The diagnosis of RLS secondary to, or associated with, 
other conditions represents a double-faceted process, as the 
problem may consist in the individuation of occult causes 
of apparently idiopathic RLS, or, on the contrary, in the 
recognition of overlooked RLS symptoms in the context of 
an overt neurological or systemic disease. The first occur-
rence is exemplified by an undisclosed iron deficiency, or 
by a mild neuropathy mainly manifesting with RLS; on the 
contrary, in the clinical context of severe diseases such as 
uremia, Parkinson disease, or multiple sclerosis, RLS may 
be disregarded in spite of its significant contribution to poor 
quality of life.
The role of polyneuropathy and its diagnostic work-up 
in RLS is controversial, in view of the uncertainty about 
its epidemiology, as discussed above. Although a statisti-
cally significant association of RLS with polyneuropathy 
has not been clearly demonstrated in overall populations of 
neuropathy, several reports suggest that RLS is frequent in 
distinct forms of polyneuropathy, especially when involv-
ing small sensory fibers,37 and this should be considered in 
a diagnostic approach.
As a practical point, patients with apparently idiopathic 
RLS of late onset and nonfamilial should be screened for 
polyneuropathy, especially when characterized by a sensory 
phenotype, and in particular for symptoms and signs of the 
small fiber series, and for possible causes of polyneuropathy 
if appropriate; on the other hand, we suggest that patients 
with polyneuropathy, especially of sensory type, should be 
questioned for symptoms of RLS as a treatable manifestation 
of the disease.
Table 1 NIH diagnostic criteria of rLS
Essential criteria
1.   An urge to move the legs, usually accompanied or caused by uncomfortable or unpleasant sensations in the legs.
2.   The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.
3.   The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the 
activity continues.
4.   The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night.
Supportive clinical features
1.    Positive family history of rLS.
2.    response to dopaminergic therapy.
3.    Periodic limb movements during wakefulness or sleep (PLMs)*.
Associated features
1.    Natural clinical course: Onset age is variable, in patients with earlier onset (50 years) the symptoms are insidious, while patients with later onset 
have a more aggressive course. rLS is usually a chronic disease with progressive clinical course; in mildest forms of rLS the clinical course can be 
static or intermittent.
2.    Sleep disturbances: disturbed sleep is usually associated to RLS, this morbidity is however aspecific.
3.    Medical evaluation/Physical examination: physical and neurological examination is generally normal (except for secondary rLS). Medical evaluation 
should be addressed to possible causes for secondary rLS.
Abbreviations: NIH, National Institutes of Health; PLMs, periodic limb movements; PLMw, periodic limb movement during wakefulness; rLS, restless legs syndrome.Clinical Interventions in Aging 2009:4 308
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Treatment
The treatment of RLS firstly demands a thorough clinical 
evaluation to rule out causes of secondary RLS, the most 
common of which is iron deficiency, and to eliminate the 
triggering factors, if any. A recommendation should be 
made to investigate the presence of neuropathy in selected 
cases, especially in nonhereditary, late-onset RLS, and/or 
in the presence of prominent sensory symptoms, in view 
of a possible treatment of the underlying condition, besides 
symptomatic therapy of RLS. It would be interesting that 
future trials explored if RLS associated with polyneu-
ropathy and/or with sensory phenotype will preferentially 
respond to particular drugs, such as antiepileptic drugs, 
rather than to dopaminergic therapy,38 as previously 
suggested.23
For primary RLS there are no treatments modifying 
the course of the disease available and the goal of different 
therapeutic strategy is to control the symptoms.
The European Federation of Neurological Sciences 
(EFNS) task force39 performed a review of the literature up 
to 2004 for the drug classes and interventions employed in 
the treatment of RLS and put forth guidelines for the man-
agement of RLS. According to EFNS guidelines, level A 
recommendations (effective in relieving the symptoms), were 
offered for cabergoline, gabapentin, pergolide, ropinirole, 
levodopa, and rotigotine by transdermal delivery, whilst other 
dopamine agonists (pramipexole, bromocriptine), valproate, 
oxycodone, carbamazepine, and clonidine were evaluated as 
probably effective (level B rating).
More recently, a task force commissioned by the Move-
ment Disorder Society (MDS) performed an evidence-based 
review of the medical literature, which included studies 
published before December 31, 2006.30 The following drugs 
were considered efficacious: levodopa, ropinirole, prami-
pexole, cabergoline, pergolide, and gabapentin. Rotigotine, 
bromocriptine, oxycodone, carbamazepine, valproic acid, 
and clonidine were considered likely efficacious. Drugs that 
were considered investigational included dihydroergocrip-
tine, lisuride, methadone, tramadol, clonazepam, zolpidem, 
amantadine, and topiramate, as well as magnesium, folic acid, 
and exercise. Intravenous iron dextran resulted likely effica-
cious for the treatment of RLS secondary to end-stage renal 
disease and investigational in RLS subjects with normal renal 
function, whereas oral iron was considered investigational, 
depending on the iron status of subjects.
According to both EFNS and MDS guidelines, the first 
line treatment for idiopathic RLS is represented by drugs that 
enhance dopaminergic neurotransmission.
Dopaminergic agents
l-Dopa/Benserazide or l-Dopa/Carbidopa
L-Dopa/Benserazide or l-Dopa/Carbidopa (100/25 mg or 
200/50 mg at bedtime) are efficacious in controlling sensory 
and motor symptoms. As a consequence of its short plasma 
half-life (1–2 hours) there is a rapidly decreasing effect 
and RLS may reappear in the second half of the night, so 
that a second dose may be needed, usually three hours after 
bedtime.35
The limitation of l-Dopa consists mainly in the phenom-
enon of “augmentation”, a condition characterized by the 
worsening of RLS severity during RLS treatment.40 Diagnos-
tic criteria for augmentation are shown in Table 2.
Prevalence of augmentation ranges from 18.6% to 
72%34,35 and seems to be more frequent with higher doses 
and longer treatment duration.36 Dosages of 300–400 mg 
should not be exceeded.
Because of augmentation and the difficulty in controlling 
symptoms for the whole night in severe RLS (even with the 
combination of standard and sustained release formulation), 
l-Dopa is best used in patients with mild RLS or intermit-
tent symptoms.
Since the use of l-Dopa is limited by its pharmacokinetic 
and pharmacodynamic characteristic, there has been a grow-
ing interest towards dopamine agonists.
ergot-derived
Pergolide and cabergoline are effective in RLS in doses of 
0.4–0.55 mg and 0.5–3 mg, respectively.34 However, because 
of their potential to induce fibrotic side effects with cardiac 
valvulopathy, they are not recommended in first-line use in 
RLS treatment and, if used, cardiopulmonary monitoring 
is required. There is insufficient evidence to make recom-
mendation about bromocriptine, α-dihydroergocriptine, and 
lisuride.30
Nonergot-derived
Extensive data are available for ropinirole and pramipexole, 
which have approval for the indication idiopathic RLS in 
USA and European Union, whereas for rotigotine, although 
likely effective, more studies are needed. Rotigotine, formu-
lated as a silicone-based transdermal patch (1–3 mg/24 h), 
improved the symptoms of RLS in two six-month trials in 
adults with idiopathic, moderate to severe RLS. Transdermal 
rotigotine was generally well tolerated, and improvements 
in RLS symptoms have been maintained in the long term. 
Further evaluations are required to ascertain if continuous Clinical Interventions in Aging 2009:4 309
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dopaminergic stimulation has the effect of limiting or pre-
venting augmentation.
Ropinirole was effective in improving the symptoms of 
RLS, compared with placebo, in patients with moderate-
to-severe primary RLS, with significant improvements 
observed within two nights of treatment,41 and was generally 
well tolerated. Significant benefits on objective measures of 
RLS motor symptoms, such as periodic leg movements, and 
on subjective measures of sleep were also demonstrated.
The main difference between the two drugs seems to 
reside in earlier efficacy of pramipexole, evident after a 
single night dose.43 Although no comparative trials have 
been published, a recent meta-analysis of pramipexole versus 
ropinirole suggested differences in efficacy and tolerability 
favoring pramipexole.44 The indirect comparison showed 
a superior reduction in the mean International RLS Study 
Group Rating scale score, higher Clinical Global Impres-
sions – Improvement scale response rate and significantly 
lower incidence of nausea, vomiting, and dizziness for 
pramipexole compared to ropinirole.
Pramipexole
Pramipexole, a nonergoline dopamine agonist with a high 
selectivity for D(2) and D(3) receptors, is the last drug 
licensed for RLS treatment. Its efficacy was first tested in 
small or uncontrolled trials,46–49 and further confirmed in more 
extensive studies, as summarized in Table 3.
Pramipexole improves both subjective symptoms of 
RLS50–52 and objective sleep parameters.53 In a double-
blind, randomized, placebo-controlled, fixed-dose trial 
on 344 patients,50 and in double-blind, randomized, 
placebo-controlled, flexible-dose trial (0.125 mg; 0.25; 0.50; 
0.75) on 345 patients,51 pramipexole improved significantly 
RLS severity and subjective sleep quality. In a polysomno-
graphic double-blind, randomized, placebo-controlled study 
on 109 RLS patients (PRELUDE),53 pramipexole signifi-
cantly reduced Periodic Limb Movements during time in bed 
Index (PLMI) and, at the dose of 0.50 mg, improved sleep 
efficiency (SE) and total sleeping time (TST).
Efficacy of pramipexole was demonstrated either after 
a single night dose,43 or in long-term therapy.54,55 Manconi 
and colleagues,43 in a single-blind, randomized, placebo-
controlled study, compared subjective and polysomnographic 
parameters at the baseline and after one night on pramipex-
ole at a single dose of 0.25 mg. They found a highly signifi-
cant reduction in VAS score and a significant reduction of 
PLMS index (the primary outcome measure), and increment 
of sleep stage 2, sleep efficacy and time in bed on the prami-
pexole night.
Long-term efficacy has been recently confirmed in an 
open-label trial on 107 patients lasting 26 weeks (PRE-
LUDE-extension)54 and in a telephone interview study on 
195 RLS patients who took pramipexole at variable doses 
(0.125–2.25) for at least one year.55 In a withdrawal trial, 
Trenkwalder and colleagues56 demonstrated very significant 
worsening of subjective RLS parameters in the group who 
discontinued pramipexole after six months of therapy. They 
also found an elevated number of dropouts (65%) in the 
placebo group, mainly due to lack of efficacy, compared to 
the drug group (9%).
Pramipexole is usually well tolerated. The discontinuation 
rate, about 20%, was similar in all the examined studies. 
Table 2 Augmentation diagnostic criteria
A. Basic features (all need to be met)
1.   The increase in symptom severity was experienced on five out of seven days during the previous week.
2.   The increase in symptom severity is not accounted for by other factors such as a change in medical status, lifestyle or the natural progression of the 
disorder.
3.    It is assumed that there has been a prior positive response to treatment.
B and C.  Additional features (one or both need to be met)
B.    Persisting (although not immediate) paradoxical response to treatment: rLS symptom severity increases some time after a dose increase and 
improves some time after a dose decrease.
C.    Earlier onset of symptoms:
    1.   An earlier onset of at least four hours
    or
    2.   An earlier onset (between two and four hours) occurs with one of the following compared to symptoms status before treatment:
      a.    Shorter latency to symptoms when at rest;
      b.    extension of symptoms to other body parts;
      c.    Greater intensity of symptoms (or increase in periodic limb movements if measured by polysomnography (PSG) or the suggested immobili-
zation test (SIT);
      d.    Shorter duration of relief from treatment.
Abbreviation: rLS, restless legs syndrome.Clinical Interventions in Aging 2009:4 310
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Table 3 Pramipexole trials in rLS
Study design Pramipexole 
administration
Outcome measure
Partinen 200653 •    Multicenter, double-blind, randomized, 
fixed-dose, placebo-controlled trial
•  randomization: 1:1:1:1:1
•    109 patients with moderate–severe 
idiopathic rLS
•  Three week period
•    Fixed doses:  
-0.125 mg 
-0.25 mg 
-0.50 mg 
-0.75 mg
•  2–3 hours before 
bedtime
•  Primary outcome: PLMI ↓
•    Secondary outcome: 
PLMSI ↓; PLMwI ↓; PLM ↓; SL ↓; time 
in delta sleep ↓ 
PLMAI →; Se →; TST → 
IrLS ↓; eSS →; SSQ ↑; SF-36 ↑ 
(improvement in social function sub-
score); PGI↑; CGI ↑
winkelman 
200650
•    Double-blind, randomized, fixed-dose, 
placebo-controlled trial
•  randomization: 1:1:1:1
•    344 patients with moderate–severe 
idiopathic rLS
•  12 week period
•    Fixed doses:  
-0.25 mg 
-0.50 mg 
-0.75 mg
•    2–3 hours before 
bedtime
•  Primary outcome: IRLS ↓
•    Secondary outcome: 
Improvement in PGI, CGI, vAS, eSS, 
rLS-QOL.
Oertel 200751 •    Double-blind, randomized, flexible-dose, 
placebo-controlled trial.
•  randomization: (placebo:pramipexole = 1:2)
•    345 patients with moderate–severe idi-
opathic rLS
•  Six week period
•   Starting dose = 0.125 mg, 
that could be increased 
by the physician to 0.25, 
0.50 or 0.75 mg/day.
•    2–3 hours before 
bedtime
•  Primary outcome: IRLS ↓
•    Secondary outcome: 
Improvement in PGI, CGI, vAS
Trenkwalder 
200657
•    Multicenter, double-blind, randomized, 
flexible-dose, placebo-controlled 
withdrawal trial.
•  randomization: 1:1
•    150 rLS patients responding to 
pramipexole on a six-month period 
were randomly assigned to receive 
placebo or to continue pramipexole 
for three months
•    Individual optimized 
dosage (0.125, 0.25, 
0.50 or 0.75 mg/die).
•    2–3 hours before 
bedtime
•  Primary outcome:
1)    CGI-I score of minimally, much or 
very much worse ↓↓ in pramipexole 
group (less than 50% reached the 
target event).
2)   An increase of IrLS to a score  15. 
↑↑ in Placebo group.
•    Secondary outcome: 
CGI-I ↑↑; CGI-S ↓↓; CGI-e ↑↑; PGI ↑; 
rLS-QOL↑
Montplaisir 
200655
• Telephone interview.
•    195 consecutives patients with 
idiopathic rLS who underwent 
pramipexole treatment for at least 
one year
•    Mean dose = 0.59 
± 0.31 mg (range = 
0.125–2.25 mg).
•    Mean treatment 
duration =  
30.5 ± 10.5 months
Questionnaire on efficacy:
– rLS severity ↓↓
– Difficulty in falling asleep ↓↓
– Nocturnal awakenings ↓↓
Manconi 200743 •    Single-blind, randomized, placebo-
controlled, fixed-dose trial.
•  randomization: 1:1
•    32 patients with severe idiopathic 
rLS, never previously treated for rLS
•    Comparison of clinical and neuro-
physiological parameters at the base-
line and after one night treatment.
•  Single dose of 0.25 mg
•    Administration  
time = 9.00 p.m.
•    Primary outcome: 
– PLMS change index: ↓
•    Secondary outcome: 
– Sleep stage 2 ↑; time in bed, sleep 
efficiency (↑) 
vAS (severity) = ↓↓
Partinen 200854 •  Open label trial
•  26 week period
•    Initial dose = 0.125 mg 
(titrated up to a  
maximum 0.75 mg)
•    Administration time = 
8.00–9.00 p.m.
•  Primary outcome: IRLS ↓
•    Secondary outcome: 
Improvement in CGI-I; PGI-I; eSS; 
SF-36; SSQ
(Continued)Clinical Interventions in Aging 2009:4 311
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Table 3 (Continued)
Study design Pramipexole 
administration
Outcome measure
Ferini-Strambi 
200852
•    Double-blind, randomized, placebo-
controlled, flexible-dose trial.
•  randomization: 1:1
•    357 patients with moderate–severe 
idiopathic rLS
•  12 week period
•    Initial dose = 0.125 
mg (titrated up to a 
maximum 0.75 mg).
•    2–3 hours before 
bedtime
•  Primary outcome:
1)  IRLS ↓
2)   MOS scale-sleep disturbance (initiation 
and maintenance) domain. ↓↓
•    Secondary outcome: 
Improvement in CGI-I; PGI-I; rLS-QOL
Abbreviations: ↑, significantly increased; ↑↑, highly significantly increased; (↑), increased but not significantly; →, unchanged; ↓, significantly decreased; ↓↓, highly significantly 
decreased; (↓), decreased but not significantly; PLMI, periodic limb movement during time in bed index; PLMSI, periodic limb movement during sleep index; PLMWI, periodic limb 
movement during wakefulness index; PLMAI, periodic limb movement during sleep with arousal index; PLM, total number of periodic limb movements; PLMS, total number of 
periodic limb movements during sleep; PLMA, total number of periodic limb movements during sleep with arousal; SL, sleep latency; SE, sleep efficiency; TST, total sleeping time; 
sreM, stage rapid eye movement sleep; rLS, restless legs syndrome; IrLS, International restless Legs Syndrome scale total score; eSS, epworth Sleepiness Scale; SSQ, subjective 
sleep quality scale; SF-36, Short Form 36 Health Survey Questionnaire PGI, Patient Global Impression scale; CGI, Clinical Global Impression scale; CGI-I, Glinical Global Impression – 
Improvement scale; CGI-S, Clinical Global Impression – Severity scale; CGI-E, Clinical Global Impression – Efficacy scale; VAS, visual analogue scale; RLS-QOL, Johns Hopkins 
restless Legs Syndrome Quality Of Life Questionnaire; SSQ, subjective sleep quality.
The incidence of adverse events was higher in the 
pramipexole group than in the placebo group, but not 
clearly dose-related. The most frequent adverse event was 
nausea, followed by fatigue, dizziness, headache, diarrhea, 
and nasopharyngitis, orthostatic hypotension and increased 
body weight. The severity of side effects was usually mild-
to-moderate. An emerging concern with dopamine agonists 
is represented by compulsive behaviors, and in particular 
gambling.57
The prevalence of side effect seems to decrease signifi-
cantly in long-term treatment (2.6%) (55 ddd) compared with 
early treatment.
Opioids
Opioids are used with increasing frequency in RLS therapy, 
especially in patients with significant daily symptoms and 
refractory RLS. However, only a few trials are available, 
concerning oxycodone (mean dose 15.9 mg),58 metha-
done (15.5 ± 7.7 mg/day),59 tramadol (50–150 mg/day).60 
Although likely efficacious, they may cause a series of 
minor and major adverse effects: dizziness, nausea, vom-
iting, urinary retention, and constipation. Respiratory 
depression and addiction potential are major concerns. 
Augmentation has been reported with long-term tramadol 
treatment.61
Conclusions
RLS seems to be a quite common condition, although prob-
ably overlooked, and it may be disabling in severe cases. 
Thus improved diagnostic knowledge of RLS is warranted, 
in order to improve quality of life using available effective 
treatments in primary RLS, and, in addition, to individuate 
and treat underlying diseases in secondary RLS.
The mainstay of symptomatic treatment is represented 
by dopamine agonists, and in particular nonergot-derived. 
In this respect, available data suggest better efficacy and 
tolerability of pramipexole.
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